Mawer Investment Management Ltd. Grows Holdings in ResMed Inc. (NYSE:RMD)

Mawer Investment Management Ltd. raised its position in shares of ResMed Inc. (NYSE:RMD - Free Report) by 3.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 76,554 shares of the medical equipment provider's stock after purchasing an additional 2,394 shares during the quarter. Mawer Investment Management Ltd. owned approximately 0.05% of ResMed worth $18,688,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Ashton Thomas Securities LLC bought a new position in shares of ResMed during the 3rd quarter worth approximately $34,000. OFI Invest Asset Management acquired a new position in shares of ResMed during the second quarter valued at about $32,000. Versant Capital Management Inc boosted its position in shares of ResMed by 196.7% during the 2nd quarter. Versant Capital Management Inc now owns 181 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 120 shares in the last quarter. Financial Connections Group Inc. acquired a new stake in shares of ResMed in the 2nd quarter valued at about $37,000. Finally, Blue Trust Inc. increased its position in ResMed by 182.7% in the 2nd quarter. Blue Trust Inc. now owns 212 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 137 shares in the last quarter. Institutional investors own 54.98% of the company's stock.

Insider Buying and Selling at ResMed

In other news, CEO Michael J. Farrell sold 14,683 shares of ResMed stock in a transaction on Monday, September 9th. The stock was sold at an average price of $248.38, for a total value of $3,646,963.54. Following the completion of the transaction, the chief executive officer now directly owns 464,169 shares in the company, valued at approximately $115,290,296.22. The trade was a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Michael J. Rider sold 882 shares of the business's stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $231.00, for a total value of $203,742.00. Following the sale, the general counsel now owns 10,512 shares in the company, valued at approximately $2,428,272. The trade was a 7.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 63,056 shares of company stock valued at $15,086,020 over the last three months. 0.71% of the stock is currently owned by insiders.

ResMed Stock Performance

RMD traded up $4.68 during trading on Monday, hitting $239.42. 756,885 shares of the company traded hands, compared to its average volume of 1,047,856. The firm has a market cap of $35.15 billion, a P/E ratio of 31.09, a price-to-earnings-growth ratio of 1.71 and a beta of 0.69. The company has a quick ratio of 1.91, a current ratio of 2.92 and a debt-to-equity ratio of 0.13. ResMed Inc. has a one year low of $148.03 and a one year high of $260.49. The stock's fifty day moving average is $242.83 and its 200 day moving average is $223.67.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts' consensus estimates of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The company had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.19 billion. During the same quarter in the previous year, the firm posted $1.64 EPS. ResMed's revenue was up 11.1% on a year-over-year basis. As a group, equities analysts predict that ResMed Inc. will post 9.28 EPS for the current fiscal year.

ResMed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Thursday, November 7th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date is Thursday, November 7th. ResMed's dividend payout ratio is currently 28.08%.

Analyst Ratings Changes

RMD has been the subject of a number of research reports. Needham & Company LLC reissued a "hold" rating on shares of ResMed in a research note on Friday, October 25th. Robert W. Baird lifted their price target on shares of ResMed from $280.00 to $283.00 and gave the company an "outperform" rating in a research report on Friday, October 25th. Bank of America upped their price objective on shares of ResMed from $240.00 to $270.00 and gave the stock a "buy" rating in a report on Thursday, September 26th. StockNews.com upgraded shares of ResMed from a "hold" rating to a "buy" rating in a report on Tuesday, October 15th. Finally, Baird R W raised shares of ResMed to a "strong-buy" rating in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, ResMed presently has an average rating of "Moderate Buy" and a consensus target price of $225.70.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.